OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER							
Policy Manual: Chi		Chil	dren's Hospital	Section/ Chapter:	Oncology		
Title:	Chemoth	erapy	y Extravasation Protocol	Policy Reference #: Supersedes #:	CHON-001		
Date of Origination:		on:	June 22, 2009	Review Date:	April 5, 2013		
<b>Revision Date:</b>			April 5, 2013				

## **PURPOSE:**

To provide pertinent information regarding the proper procedure for the management of extravasation of cytotoxic drugs

## **DEFINITIONS:**

Some chemotherapeutic agents are considered vesicants and may cause serious tissue damage if they leak into tissue outside of the vein (extravasate). Extravasation is the inadvertent administration of a vesicant into the surrounding tissues that can cause pain, burning, inflammation, necrosis, sloughing, and / or ulceration of the tissue. Irritants are those agents that can inflame tissue but will not cause tissue necrosis if extravasation occurs; reactions range from mild erythema and burning to pain and inflammation at the injection site. Flare reactions may include erythema, urticaria, and phlebitis along the vein. The degree of tissue damage related to an extravasation is dependent upon the vesicant potential of the agent and the concentration and quantity of drug extravasated.

## **POLICY:**

The extravasation protocol should be initiated as soon as an extravasation of a vesicant/irritant is suspected.

Initiate the following steps in the event of any extravasation of a chemotherapeutic agent.

- 1. Stop the administration of the chemotherapy infusion.
- 2. Notify the physician at the time of the occurrence and obtain orders for treatment
- 3. Put on chemotherapy gloves to minimize personal exposure to any chemotherapeutic agent in blood.
- 4. Withdraw as much drug from the site as possible through the existing needle and IV tubing.
- 5. Elevate and immobilize the site.
- 6. Apply warm or cool compresses for 15 minutes at least 3-4 times a day for the first 24-48 hours. (see chart below as a reference)
- 7. Do not rub or press on the area.
- 8. Observe the site for pain, erythema, induration, and/or necrosis.
- 9. Document the following:
  - a. Date
  - b. Time
  - c. Type of access
  - d. Location of access
  - e. Drug sequence
  - f. Drug administration technique
  - g. Approximate drug amount extravasated
  - h. Patient response

- i.
- Appearance of the site Physician notification j.
- Follow up measures k.
- 1. Document the incident according to institutional policy. Notify risk management, if indicated.

nl)	Cold Cold Cold Cold Cold Cold Cold Cold	NoneNoneSodium ThiosulfateSodium ThiosulfateNone vs. DMSONoneTopical DMSO 99% vs.Dexrazoxane IVTopical DMSO 99% vs.Dexrazoxane IVNormal Saline vs.Hyaluronidase SC vs.Topical DMSO 99%
	Cold Cold Cold Cold Cold Cold Cold	Sodium Thiosulfate Sodium Thiosulfate None vs. DMSO None Topical DMSO 99% vs. Dexrazoxane IV Topical DMSO 99% vs. Dexrazoxane IV Normal Saline vs. Hyaluronidase SC vs.
	Cold Cold Cold Cold Cold Cold	Sodium ThiosulfateNone vs. DMSONoneTopical DMSO 99% vs.Dexrazoxane IVTopical DMSO 99% vs.Dexrazoxane IVNormal Saline vs.Hyaluronidase SC vs.
	Cold Cold Cold Cold Cold	None vs. DMSONoneTopical DMSO 99% vs.Dexrazoxane IVTopical DMSO 99% vs.Dexrazoxane IVNormal Saline vs.Hyaluronidase SC vs.
	Cold Cold Cold Cold	NoneTopical DMSO 99% vs.Dexrazoxane IVTopical DMSO 99% vs.Dexrazoxane IVNormal Saline vs.Hyaluronidase SC vs.
	Cold Cold Cold	Topical DMSO 99% vs. Dexrazoxane IV Topical DMSO 99% vs. Dexrazoxane IV Normal Saline vs. Hyaluronidase SC vs.
	Cold	Dexrazoxane IV Topical DMSO 99% vs. Dexrazoxane IV Normal Saline vs. Hyaluronidase SC vs.
	Cold	Dexrazoxane IV Normal Saline vs. Hyaluronidase SC vs.
		Hyaluronidase SC vs.
	Warm	- F
	vv arm	Hyaluronidase (only for a large infiltration)
	Cold	None
	Cold	Topical DMSO 99% vs. Dexrazoxane IV
	Cold	None vs. DMSO
	Cold	None
	Cold	None
	Cold	Topical DMSO 99%
	Cold	Topical DMSO 99%
cant DO	WARM NOT APPLY COLD	Sodium Thisulfate
	Cold	Normal Saline vs. Topical DMSO 99%
	Cold	None
	Warm	Hyaluronidase
		Hyaluronidase
	Warm	Tryalutomuase
		Cold Warm

## **REFERENCES:**

Kline, N. E. (ED.). (2011) <u>The Pediatric Chemotherapy and Biotherapy Curriculum.</u> (3<sup>rd</sup> ed.) Glenview, IL: Association of Pediatric Hematology/Oncology Nurses.